ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Salix To Acquire Santarus

by Ann M. Thayer
November 18, 2013 | APPEARED IN VOLUME 91, ISSUE 46

Salix Pharmaceuticals is buying the San Diego-based specialty pharmaceutical firm Santarus through a $2.6 billion stock purchase. Santarus acquires and develops proprietary products and has five products on the market in the areas of gastrointestinal disorders, diabetes, and high cholesterol. Raleigh, N.C.-based Salix also develops gastroenterology treatments. Combined product revenues of the two companies should reach about $1.3 billion in 2013, Salix says. The companies expect to complete the transaction in the first quarter of 2014.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment